Literature DB >> 16138435

Renal dysfunction after oral acyclovir treatment in a geriatric woman: a case report.

Burcu Balam Yavuz1, Mustafa Cankurtaran, Meltem Halil, Neslihan Dagli, Alper Kirkpantur.   

Abstract

Oral acylovir treatment rarely results in renal dysfunction. In reported cases concerning renal failure due to oral acyclovir, baseline creatinine levels were unknown or impaired or a predisposing factor for nephrotoxicity was present. We report a 78-y-old female with documented normal baseline renal function and no contributing possible nephrotoxic factor, who developed irreversible renal dysfunction after oral acyclovir treatment. We suggest that in geriatric age groups chronic renal insufficiency should be taken into consideration during oral acyclovir therapy.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16138435

Source DB:  PubMed          Journal:  Scand J Infect Dis        ISSN: 0036-5548


  5 in total

1.  Famciclovir as an antiviral agent for a patient with acute renal failure.

Authors:  Hyonok Yoon; Ki Yon Rhew
Journal:  Int J Clin Pharm       Date:  2013-01-01

2.  Acute renal injury induced by valacyclovir hydrochloride: A case report.

Authors:  Yanning Zhang; Yuxi Cong; Yan Teng
Journal:  Exp Ther Med       Date:  2016-11-15       Impact factor: 2.447

3.  Clinical study of Gene-Eden-VIR/Novirin in genital herpes: suppressive treatment safely decreases the duration of outbreaks in both severe and mild cases.

Authors:  Hanan Polansky; Edan Itzkovitz; Adrian Javaherian
Journal:  Clin Transl Med       Date:  2016-10-20

4.  Clinical study in genital herpes: natural Gene-Eden-VIR/Novirin versus acyclovir, valacyclovir, and famciclovir.

Authors:  Hanan Polansky; Adrian Javaherian; Edan Itzkovitz
Journal:  Drug Des Devel Ther       Date:  2016-08-29       Impact factor: 4.162

5.  Clinical Trial of Herbal Treatment Gene-Eden-VIR/Novirin in Oral Herpes.

Authors:  Hanan Polansky; Adrian Javaherian; Edan Itzkovitz
Journal:  J Evid Based Integr Med       Date:  2018 Jan-Dec
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.